Category | Diagnostic strategies | Effectiveness (%) | ΔEa (%) | Costs (€) | ΔCb (€) | ΔREc (μSv) |
---|---|---|---|---|---|---|
Women | ||||||
Base case | No screening | 54.6 | 60 | |||
Do screeninge | 23.3 | −31.3 | 1027 | 967 | 1427 | |
X-ray following VFA | 25.2 | −29.4 | 881 | 821 | 747 | |
VFA | 25.2 | −29.4 | 1202 | 1142 | 141 | |
X-ray | 19.6 | −35.0 | 998 | 938 | 3394 | |
Multivariate sensitivity (Cl = 1 year) | No screening | 54.6 | 60 | |||
Do screeninge | 23.2 | −31.4 | 1102 | 1042 | 2455 | |
X-ray following VFA | 24.8 | −29.7 | 862 | 802 | 996 | |
VFA | 24.8 | −29.7 | 1418 | 1358 | 254 | |
X-ray | 19.9 | −34.7 | 1025 | 966 | 6115 | |
Men | ||||||
Base case | No screening | 22.5 | 27 | |||
Do screeninge | 8.4 | −14.2 | 658 | 630 | 1416 | |
X-ray following VFA | 10.1 | −12.5 | 504 | 477 | 556 | |
VFA | 10.1 | −12.5 | 927 | 899 | 147 | |
X-ray | 5.0 | −17.5 | 542 | 515 | 3545 | |
Multivariate sensitivity (Cl = 1 year) | No screening | 54.6 | 60 | |||
Do screeninge | 8.3 | −14.2 | 734 | 707 | 2526 | |
X-ray following VFA | 10.1 | −12.4 | 498 | 471 | 828 | |
VFA | 10.1 | −12.4 | 1143 | 1116 | 267 | |
X-ray | 4.8 | −17.7 | 560 | 533 | 6483 | |
Totald | Do screeninge | 16.4 | −23.3 | 854 | 810 | 1422 |